Efficacy of antiretroviral therapy switch in HIV-infected patients: A 10-year analysis of the EuResist cohort

Intervirology

Volumn 55, Issue 2, 2012, Pages 160-166

  Oette, Mark ^a   Schülter, Eugen ^b   Rosen Zvi, Michal ^e   Peres, Yardena ^d   Zazzi, Maurizio ^h   Sönnerborg, Anders ^f   Struck, Daniel ^g   Altmann, André ^c   Kaiser, Rolf ^b  

^a Augustinerinnen Hospital   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^d Health Care and Life Sciences Group   (Israel)

^e IBM HAIFA RESEARCH LAB   (Israel)

^f KAROLINSKA INSTITUTE   (Sweden)

^g LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^h UNIVERSITY OF SIENA   (Italy)

Author keywords

Drug efficacy; EuResist; Highly active antiretroviral therapy; Treatment switch

Indexed keywords

ARTICLE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856474362     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000332018     Document Type: Article

References (17)

1. Pallella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks TJ, Holmberg S-grave, HIV Outpatient Study Investigators: Mortality in the highly active antiretroviral era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006;43:27-34.
2. Vo TTN, Lebergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Weber R, Swiss Cohort Study: Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008;197:1685-1694.
3. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C, Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS), CO3 AQUITAINE Study Group: HIV-infected adults with a C-grave4 cell count greater than 500 cells/mm 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-77.
4. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman D-grave: Antiretroviral drug resistance testing in adult HIV-1 infection:2008 recommendations of the International AI-graveS Society - USA panel. Clin Infect Dis 2008;47:266-285.
5. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren J-grave: Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AI-graveS 2008;22:2187-2198.
6. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT, HOPS (HIV Outpatient Study) Investigators: The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84.
7. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, De Masi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.
8. Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A: Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study. J Clin Virol 2009;46:290-294.
9. Altmann A, Rosen-Zvi M, Prosperi MCF, Aharoni E, Neuvirth H, Schülter E, Büch J, Struck D, Peres Y, Incardona F, Sönnerborg A, Kaiser R, Zazzi M, Lengauer T: Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS ONE 2008;3:e3470.
10. Prosperi MCF, Rosen-Zvi M, Altmann A, Zazzi M, Di Giambenedetto S, Kaiser R, Schülter E, Struck D, Sloot P, van de Vijver DA, Vandamme A-M, Sönnerborg A, EuResist and Virolab study groups: Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS ONE 2010;5:e13753.
11. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group: Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-1492.
12. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 study group: Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49:1259-1267.
13. Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari E, Gatell JM, ATAZIP Study Group: Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving an LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009;51:29-36.
14. Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group: Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AI-graveS 2010;24:1697-1707.
15. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman D-grave, Volberding PA, Yeni P, Schooley RT: Antiretroviral treatment of adult HIV infection:2010 recommendations of the International AI-graveS Society - USA panel. JAMA 2010;304:321-333.
16. Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; Clin Surv-Studiengemeinschaft: Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy. Dtsch Med Wochenschr 2010;135:1166-1170.
17. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren J-grave, Euro-SI-graveA Study Group: History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med 2010;11:469-478.